Distinct peripheral T-cell and NK-cell profiles in HGBL-<i>MYC/BCL2</i> vs patients with DLBCL NOS
A. Vera de Jonge(Amsterdam University Medical Centers), Tuna Mutis(Amsterdam University Medical Centers)
Cited by 9
Related Papers
Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment
|Blood Cancer Journal|2021|95
Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design
|PLoS ONE|2018|73
Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies
|Cancers|2020|72
DuoHexaBody-CD37®, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies
|Blood Cancer Journal|2020|70
CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering
|Haematologica|2019|62